Anktiva (nogapendekin alfa inbakicept-pmln intravesical solution) — Cigna
Non-Muscle Invasive Bladder Cancer (BCG-unresponsive, high-risk disease with carcinoma in situ)
Initial criteria
- Patient age ≥ 18 years
- Patient has high-risk Bacillus Calmette-Guerin (BCG) unresponsive disease
- Patient has carcinoma in situ (CIS)
- Medication is used in combination with BCG
- Medication is prescribed by or in consultation with a urologist or an oncologist
Reauthorization criteria
- Patient has an ongoing complete response defined as ONE of the following: (a) Patient has negative cystoscopy and EITHER negative urine cytology OR malignant urine cytology if cancer found in the upper tract or prostatic urethra and random bladder biopsies are negative; OR (b) Patient has positive cystoscopy with biopsy-proven benign or low-grade Ta non-muscle invasive bladder cancer and negative urine cytology
- Medication is used in combination with BCG
- Medication is prescribed by or in consultation with a urologist or an oncologist
Approval duration
initial 6 months; maintenance 3 months